RxDoctor Payments Data

Bernadette Marturano

Family · Charleston, WVNPI 1275882292

Payments from drug & device makers

$985in general payments, 2019–2025

Across 13 payments — averaging $75.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$233
  • Novo Nordisk$158
  • Astellas Pharma US Inc$129
  • AstraZeneca$125
  • Lilly USA, LLC$115
  • Boehringer Ingelheim$100
  • plus $126 from 2 others

What the payments were for

  • Food & beverage$985100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$985 in reported general payments places this provider in the 65th percentile of 1,507 family providers in West Virginia.

See all family providers in West Virginia

Medicare billing

Part B allowed, 2024
$47,028
Medicare patients
641
Services billed
876

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban44$13,080
TradjentaLinagliptin41$6,884
Pantoprazole Sodium51$922
Colestipol Hcl13$894
Potassium Chloride55$496
Amlodipine Besylate51$461
Atorvastatin Calcium19$441
Ondansetron Hcl20$427
Losartan Potassium21$382
Gabapentin68$346
Escitalopram Oxalate44$334
Metoprolol Tartrate37$290
Lorazepam31$259
Oxycodone Hcl17$231
Levothyroxine Sodium44$224

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimTradjenta$100$6,88441 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,507 family providers in West Virginia.

Other family in Charleston

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →